Malignancy validation in a United States registry of rheumatoid arthritis patients

[1]  A. Zeringue,et al.  Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. , 2011, Rheumatology.

[2]  W. Dixon,et al.  A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. , 2010, Seminars in arthritis and rheumatism.

[3]  J. Kremer,et al.  Interpreting registry-derived drug studies: does societal context matter? , 2009, Arthritis and rheumatism.

[4]  S. Ramsey,et al.  Sensitivity of Administrative Claims to Identify Incident Cases of Lung Cancer: A Comparison of 3 Health Plans , 2009, Journal of managed care pharmacy : JMCP.

[5]  R. Cress,et al.  Risk of cancer among rheumatoid arthritis patients in California , 2009, Cancer Causes & Control.

[6]  L. Jacobsson,et al.  Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register , 2008, Annals of the rheumatic diseases.

[7]  G. Caldito,et al.  Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. , 2008, The Journal of rheumatology.

[8]  F. Wolfe,et al.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. , 2007, Arthritis and rheumatism.

[9]  F. Wolfe,et al.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. , 2007, Arthritis and rheumatism.

[10]  S. Schneeweiss,et al.  Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data , 2007, Cancer Causes & Control.

[11]  L. Biancone,et al.  Treatment with biologic therapies and the risk of cancer in patients with IBD , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[12]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[13]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[14]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[15]  F. Wolfe,et al.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. , 2005, The Journal of rheumatology.

[16]  J. Kremer,et al.  The CORRONA database. , 2006, Autoimmunity reviews.

[17]  L. Jacobsson,et al.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[18]  L. Jacobsson,et al.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[19]  H. Olsson,et al.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas , 2005, Annals of the rheumatic diseases.

[20]  F. Wolfe,et al.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. , 2004, Arthritis and rheumatism.

[21]  M. Greene,et al.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.

[22]  J. M. Cash,et al.  Does methotrexate increase the risk of infection or malignancy? , 1997, Rheumatic diseases clinics of North America.

[23]  J. Klippel,et al.  Second-line drug therapy for rheumatoid arthritis. , 1994, The New England journal of medicine.

[24]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[25]  J. F. Fraumeni,et al.  Incidence of cancer among patients with rheumatoid arthritis. , 1993, Journal of the National Cancer Institute.